Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05959109 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT05959109 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 57 participants.
The verdict
NCT05959109, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The main purpose of this study is to look at the amount of the study drug, peresolimab, that gets into the blood stream and how long it takes the body to get rid of it when given under the skin using test formulations versus reference formulation in healthy participants. The study will also evaluate the safety and tolerability of peresolimab and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 17 weeks, including screening.
Interventions
- DRUG Peresolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2024-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05959109
The ClinicalTrials.gov registry entry for NCT05959109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peresolimab is the first listed.
NCT05959109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05959109 about?
NCT05959109 is a clinical study titled "A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants". The main purpose of this study is to look at the amount of the study drug, peresolimab, that gets into the blood stream and how long it takes the body to get rid of it when given under the skin using test formulations versus reference formulation in healthy participants. The study will also evaluate...
What is the current status of trial NCT05959109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2023-07-21. Estimated completion is 2024-01-11.
What interventions are being tested in trial NCT05959109?
The interventions under investigation include: Peresolimab (DRUG).
Who is sponsoring clinical trial NCT05959109?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.